The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Teijin Pharma: Bonalon IV Infusion Approved as Japan’s 1st Once-a-Month IV Drug for Osteoporosis
January 20, 2012
- Takeda to Cut 2,800 Jobs in US, Europe by Integrating Operation Sites
January 19, 2012
- Takeda President Hasegawa Envisions Japanese National as Successor
January 19, 2012
- Takeda’s Next Core Product, Novel ARB Azilva Approved
January 19, 2012
- Senju Obtains Approval for Glaucoma Treatment Aiphagan
January 19, 2012
- Daiichi Sankyo to Copromote 1st Antibody Drug with AstraZeneca
January 19, 2012
- Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey
January 18, 2012
- AZ Appeals Effectiveness of Faslodex as Secondary Treatment
January 18, 2012
- BTMU Forecast 1% Growth in 2012 Domestic Ethical Drug Market
January 18, 2012
- Hisamitsu Starts Capital, Business Alliance with Yutoku Following Acquisition of 15% of Its Shares
January 18, 2012
- Eisai: Insomnia Treatment Lunesta Approved
January 18, 2012
- Astellas: Regnite Approved for RLS
January 18, 2012
- MSD: Cancidas Approved for Treatment of Deep Mycoses
January 18, 2012
- Otsuka: Abilify Obtains Add’l Indication for Manic Symptoms in Bipolar Disorder, OD Tablets as Well
January 18, 2012
- MSD: Rotavirus Vaccine RotaTeq Oral Solution Approved
January 18, 2012
- Nobelpharma and Eisai Launch Anticonvulsant Agent Fostoin on Jan. 17
January 17, 2012
- MTPC Licenses Hib Vaccine from Nuron Biotech
January 17, 2012
- 38% of Doctors Will Attend Company-Sponsored Events Only if Transportation, Lodging Costs Are Paid: Survey
January 17, 2012
- 100th Acquisition/License Support Agreement Reached through LSIP Fund
January 17, 2012
- MTPC Issues Apology for Its Researcher’s Arrest on Suspicion of Bodily Harm
January 16, 2012
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…